Perspective Therapeutics (CATX) to Release Earnings on Wednesday

Perspective Therapeutics (NYSE:CATX) is expected to post its quarterly earnings results after the market closes on Wednesday, March 26th. Analysts expect Perspective Therapeutics to post earnings of ($0.26) per share for the quarter.

Perspective Therapeutics Stock Up 1.2 %

Perspective Therapeutics stock opened at $2.52 on Monday. The business has a 50 day moving average of $3.03 and a 200-day moving average of $6.75. Perspective Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.05.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 17th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $24.00 to $5.00 in a research report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and a consensus price target of $14.56.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.